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ABSTRACT: Molecular probes that selectively highlight pancreatic cancer (PC)
tissue have the potential to improve pancreatic ductal adenocarcinoma (PDAC)
margin assessment through the selective highlighting of individual PC cells.
Herein, we report a simple and unique family of systematically modiﬁed red and
near-infrared ﬂuorescent probes that exhibit a ﬁeld-eﬀect-derived redshift. Two of
thirteen probes distributed to the normal mouse pancreas following systemic
administration. One selectively accumulated in genetically modiﬁed mouse models
of PDAC. The probe exhibited intracellular accumulation and enabled
visualization of four levels of the structure, including the whole organ, resected
tissue, individual cells, and subcellular organelles. In contrast to the small-molecule
probes reported previously, it possesses an inherent aﬃnity toward PDAC cells
and thus does not require conjugation to any targeting agent. The ﬂuorescent
probe can thus promote new strategies not only for precision image-guided
surgery, but also for PC detection, monitoring of therapeutic outcomes, and basic
research.

■

INTRODUCTION
It was estimated that approximately 53 000 people would have
been diagnosed with pancreatic cancer (PC) in the United
States in 2016 and would have had a postdiagnosis life
expectancy of 5−7 months.1 PC is projected to become the
second leading cause of cancer-related death by 2030.2
Pancreatic ductal adenocarcinoma (PDAC) is the most
prevalent form of PC. Current screening for PDAC using
techniques such as magnetic resonance imaging and computed
axial tomography is relatively expensive and ineﬀective, as over
half of all cases are diagnosed after metastasis has occurred,
limiting treatment options. Surgical resection is the treatment
of choice because chemotherapy and/or radiation therapy alone
do not signiﬁcantly improve life expectancy.3 Unfortunately,
surgical resection is only possible in 15−20% of cases.4
Moreover, to date there has been no intraoperative guidance
to diﬀerentiate malignant pancreas from normal pancreatic
tissues. PC and healthy tissue are currently distinguished
through white light visualization and palpation as well as by
rapid frozen section (FS) analysis using histopathological
pattern recognition through standard hematoxylin and eosin
(H&E) staining while the surgical resection is in progress.5
Intraoperative assessment of PDAC margin status during
surgery is challenging using current technology. Nearly 75% of
all patients have residual disease from margins not assessed by
FS analysis. Limitations of FS analysis include negative
assessments due to time constraints in the operating room
© 2017 American Chemical Society

and microscopic metastases not detected at the time of
surgery.6 In addition, cellular architecture distortion and tissue
artifacts are common issues that occur during FS sample
preparation. Slides produced by formalin-ﬁxed paraﬃnembedded tissue processing would be highly desirable over
FS-based H&E; however, it is well known that the tissue
processing time is too lengthy for intraoperative use.
Fluorescence imaging has the potential to improve PDAC
detection during surgery via the use of highly tumor-speciﬁc
molecular probes to facilitate tumor identiﬁcation. It oﬀers the
potential for less subjective, rapid, real-time ex vivo
conﬁrmation of negative margin status during surgery. Nearinfrared (NIR) ﬂuorophores have excitation and emission
maxima between 650 and 900 nm, where hemoglobin and H2O
have their lowest absorption coeﬃcients. Moreover, NIR
phonons cause minimal photoinduced damage to biological
samples and have relatively high tissue penetration depth and
signal-to-background ratios (SBRs). Therefore, NIR probes can
enhance the overall image quality and collection time.
However, to date there are no clinically approved PC-speciﬁc
ﬂuorescent dyes. Commercially available dyes, including the
only FDA-approved in vivo ﬂuorescent contrast agents,
indocyanine green, methylene blue (MB), and ﬂuorescein,
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exhibit nonspeciﬁc ﬂuorescence and largely act as blood pool
agents.

solvatochromic eﬀects (Figure S5). In aqueous solution, the
hydroxyl forms of 1, 3, 5, and 11 were red emitting, whereas
their conjugate bases exhibited NIR ﬂuorescence. Solvent
dependence is at least partially attributable to diﬀerences in the
equilibria between tautomeric forms of the compounds in the
various solvents tested. Solvent and pH sensitivity were
addressed via derivatization. Methoxy-functionalized analogues
(2, 4, 6, and 12) displayed relatively bright red ﬂuorescence and
were independent of variations in pH (Figures S6 and S7) and
solvent composition (Figure S7). Replacing the hydroxyl group
with an amine generated a series of NIR-emitting seminaphthorhodamines (9, 10, and 13). The spectral properties of
9, 10, and 13 were pH independent and only modestly
dependent on solvent composition (Figure S8). Transposition
of the hydroxyl and amine functionalities in seminathorhodaﬂuors 3 and 5 generated compounds 7 and 8. This lowered
their pKa values, resulting in spectral properties that were not
pH dependent in the physiological range.
Compounds 2, 12, and 13 are representative of the three
classes of benzo[c]xanthenes designed in this study and were
chosen as candidates for initial in vivo and ex vivo screening for
pancreas and PDAC targeting based on the following
considerations. First, their predicted physiochemical properties
(Figures S1−S3) cover a relatively broad range of log D values,
enabling evaluation of the inﬂuence of lipophilicity on targeting.
Second, each exhibits desirable pH independence. Third, their
spectral properties (Figures S6−S8) show that they have the
highest quantum yield and brightness within each of the three
classes of benzo[c]xanthenes. The predicted physicochemical
properties of 2, 12, and 13 are shown in Figure 3, allowing
correlation between the in vitro and in vivo targeted
localization and the molecular characteristics of the synthesized
ﬂuorophores. In vitro cell viability (Figure S10A) and timedependent ﬂuorophore uptake (Figure S10B) were assessed in
the presence of compounds 2, 12, and 13 in Capan-1 cells (a
representative PDAC cell line). The cytotoxicity studies
demonstrated that compound 2 was the least toxic (IC50
30.08 μM), followed by compounds 13 (IC50 26.08 μM) and
12 (IC50 17.79 μM). Each ﬂuorophore exhibited similar
kinetics, demonstrating uptake within 30 min of ﬂuorophore
application. Compound 13 exhibited the greatest uptake and 2
the lowest during this period.
The subcellular localization of 2, 12, and 13 was investigated
in Capan-1 cells after 1 h incubation. Organelle-speciﬁc
ﬂuorescent probes were used to assess the site-speciﬁc uptake
of each ﬂuorophore. The preferential intracellular localization
of compound 2 (Figure S10C) was within vesicular structures
that may embody lipid droplets, endosomes, or other
membrane-based vesicles. In contrast to 2, compounds 12
(Figure 4) and 13 (Figure S10E) demonstrated more
homogeneous distribution across cells with extensive accumulation in the mitochondria (Mito) as well as limited
accumulation in the nucleus and endoplasmic reticulum (ER).
12 and 13 are cationic, and they distribute electrophoretically in
the mitochondrial matrix in response to the electric potential
across the mitochondrial membrane.16
The initial biodistribution proﬁle screening of 2, 12, and 13
was carried out in healthy CD-1 mice and compared to that of
MB to assess their pancreas speciﬁcity (Figure 5). Compound
12 exhibited the highest and most persistent ﬂuorescence SBR
in the pancreas as compared to that in the surrounding organs
at the 4 h time point. It had a 4-fold higher uptake in normal
pancreas tissue as compared to that of previously studied MB

■

RESULTS AND DISCUSSION
One of the main challenges in PDAC therapy is drug delivery
and is largely attributed to the hypovascular and ﬁbrotic tumor
microenvironment.7 Thus, to attain desirable PDAC-selective
accumulation and SBR, we have synthesized a focused library of
systematically modiﬁed 1-substituted benzo[c]xanthene ﬂuorophores (Figure 1) to begin to deﬁne factors modulating tissue

Figure 1. 1-Substituted benzo[c]xanthene library.

biodistribution,8 such as probe size, lipophilicity, solubility, and
ionization state. To minimize the eﬀects of autoﬂuorescence,
these compounds were designed to exhibit signiﬁcant bathochromic shifts compared to traditional long-wavelength 3substituted benzo[c]xanthenes via the formal repositioning of
polar groups.9−12
Compounds 1−13 (Figure 1) were designed taking into
account the uptake and related “drug-like” properties that can
be used as quantitative descriptors for predicting and
optimizing biodistribution and tissue targeting.13 The predicted
absorption spectra and physicochemical properties of 1−13 are
shown in Figures S1−S3 (Supporting Information (SI)).
Compounds 1−13 exhibit maximum absorption peaks between
400 and 650 nm and are within the requirements to be
considered for tissue targeting according to the Lipinski14 and
Veber15 rules. Log D values ranged from 0.5 to 5 (Lipinski rule:
<5), molecular weights were between 400 and 500 g/mol
(Lipinski rule: <500 g/mol), 0−4 hydrogen bond donors
(Lipinski rule: <5) and 4−5 hydrogen bond acceptors (Lipinski
rule: <10) were present, and polar surface areas ranged between
48 and 87 Å2 (Veber rule: <140 Å2). Experimental details for
the synthesis of each compound are provided in the SI.
The spectral properties of this series of probes (1−13), based
on seminaphthoﬂuorescein, seminaphthorhodaﬂuor, and seminaphthorhodamine scaﬀolds, were screened for pH and solvent
dependence (Figure 2, Table 1, and Figures S4−S9).
Absorption and ﬂuorescence spectra of compounds containing
ionizable hydroxyl groups (seminaphthoﬂuorescein 1 and
seminaphthorhodaﬂuors 3, 5, and 11) exhibited pH dependence over the physiological range (Figures S4 and S5) and
155

DOI: 10.1021/acsomega.6b00403
ACS Omega 2017, 2, 154−163

ACS Omega

Article

Figure 2. Spectral properties of compounds 1−13 at various pH values. (A) Absorption spectra (solid lines) and normalized ﬂuorescence emission
spectra (dash lines) of pH-dependent seminaphthoﬂuorescein and seminaphthorhodaﬂuors (1, 3, 5, and 11) in acidic solution (pH 1.9, HCl). (B)
Conjugate bases of 1, 3, 5, and 11 in basic solution (pH 12.1, NaOH). (C) pH-independent seminaphthoﬂuorescein and seminaphthorhodaﬂuors
(2, 4, 6, and 12) in pH 7.4 buﬀer. (D) pH-independent seminaphthorhodamines (9, 10, and 13) in pH 7.4 buﬀer. (E) Conjugate acids of transposed
seminaphthorhodaﬂuors (7 and 8) in acidic solution (pH 1.9, HCl). (F) 7 and 8 in basic solution (pH 12.1, NaOH). Fluorophore concentrations
range from 10 to 15 μM. Aqueous solutions contain 10% DMSO and 12.5 mM HCl, NaOH or pH 7.4 buﬀer. Red-emitting ﬂuorophores were
excited at 480 or 510 nm, and NIR-emitting ﬂuorophores were excited at 630 nm. Emission spectra are normalized to their corresponding absorption
peaks. Excitation Emission Matrices (EEMs) are provided in the SI.

(log D = −0.62). MB extravasated to some degree but
demonstrated poor penetration into normal pancreas tissue
(Figure S11). The low in vivo eﬃcacy of MB could be
attributed to its relatively low lipophilicity and high water
solubility, as it is preferentially and rapidly cleared through the
renal system after systemic administration. MB’s low tissue
ﬂuorescence, rapid clearance rate, and reduced bioavailability
limited its pancreas tissue selectivity and thus its potential for
image-guided surgery applications. From the study herein,
higher log D value compounds 2 and 12 exhibited improved
pancreas speciﬁcity, whereas 13 and MB had relatively lower
log D values and diminished pancreas accumulation, which
correlates well with previous studies.13,17
Genetically engineered mouse models of PDAC tumors that
recapitulate the clinical, pathological, and genomic features of
human PDAC18,19were used to assess the speciﬁcity of the
designed ﬂuorophores for PDAC accumulation both in vivo
and ex vivo. Compound 12, which aﬀorded the highest
pancreas tissue uptake in healthy mice, was chosen for further
study in the genetically modiﬁed PDAC tumor-bearing mouse
model. Ex vivo staining of pancreas tissue derived from healthy

and PDAC mice showed that their characteristic features were
highlighted by 12 (Figure 6A). The healthy mouse pancreas
tissue showed uptake of 12 in its abundant acinar cell
population. In contrast, in the cancerous tissue, 12 localized
in the PDAC-associated ductal epithelial cells, enabling them to
be observed via an increased ﬂuorescence signal that was
visually brighter compared to that of the acinar cells in the
healthy tissue. Thus, 12 enabled ex vivo staining to distinguish
the features of healthy and PDAC tissue ex vivo (Figure 6A).
Compound 12 was systemically administered to n = 5
genetically modiﬁed PDAC mice. Pancreas-speciﬁc ﬂuorescence
was monitored over a 1.5 h period. Signiﬁcantly more
ﬂuorescence was seen in compound 12-injected PDAC-bearing
animals compared to that in uninjected control PDAC-bearing
animals (Figure 6B,C). After euthanasia, the pancreas was
assessed microscopically for PDAC-speciﬁc ﬂuorophore accumulation. Representative intraoperative ﬂuorescence images
over time as well as the in vivo organ biodistribution kinetics of
compound 12 are shown in Figure S12.
Representative serially sectioned tissues stained with pancytokeratin to assess PDAC speciﬁcity of compound 12
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also demonstrated colocalization with the pan-cytokeratin
immunoﬂuorescence staining. This supports studies that have
shown that genetic mutations of acinar cells are associated with
precancerous pancreatic intraepithelial neoplasia that progresses to PDAC over time.21,22

Table 1. Tabulated Spectral Properties of Compounds 1−13
at Various pH Valuesa
compound

λmax abs, nm
(ε, M−1 cm−1)

λmax em, nm
(φ, %)

1
2
3
4
5
6
7
7
8
9
10
11
12
13

530 (12 167)
530 (15 610)
542 (19 787)
538 (21 742)
567 (20 399)
568 (22 470)
509 (8300)
549 (5664)
530 (8834)
576 (13 872)
598 (17 066)
585 (15 134)
582 (17 764)
601 (12 808)

600
580
604
596
614
606
530
750
530
760
770
624
622
740

(1.17)
(46.49)
(1.14)
(34.42)
(4.09)
(9.32)

(0.18)
(0.20)
(15.3)
(11.38)
(0.66)

Stokes
shift
(nm)
70
50
62
58
47
38
21
201
21
184
172
39
40
139

brightness

pKa

142
7257
226
7484
834
2094

7.72

25
34
2314
2022
85

■

CONCLUSIONS
In summary, the synthesis of a focused probe library with
predictable physicochemical properties aﬀorded a simple
molecular probe (12), enabling the imaging of PDAC in a
genetically engineered mouse model both in vivo and ex vivo,
providing the opportunity for dual clinical utility. Compound
12 oﬀers highly attractive characteristics, such as high contrast,
tumor speciﬁcity, and adaptation to clinical and intraoperative
workﬂows. Conjugation to a biological targeting agent was not
required for PDAC tumor speciﬁcity. Compound 12
functioned at the level of the whole organ, enabling
visualization of a cancerous pancreas with excellent SBR. It
targeted PDAC tissue and cells as evidenced by comparison
with H&E staining and the immunohistochemistry pancytokeratin assay, and it allowed for ready distinction between
individual cell morphologies. At the subcellular level, it
demonstrated accumulation in the mitochondria. Compound
12 is highly tumor speciﬁc, enabling the imaging of PDAC at
four diﬀerent levels of structure in a genetically engineered
mouse model. It thus possesses desirable properties for
promoting enhanced PC detection, therapeutic monitoring,
and image-guided surgery.

6.67
6.82

7.84

a
Fluorophore concentrations range from 10 to 15 μM. Aqueous
solutions contain 10% DMSO and 12.5 mM HCl, NaOH or pH 7.4
phosphate buﬀer. Tabulated spectral properties of conjugate bases of
1, 3, 5, and 11, as well as conjugate acids of 7 and 8 are provided in the
SI.

conﬁrmed that accumulation of compound 12 in the PDAC
tumor tissue was signiﬁcantly higher than that in the
surrounding tissues and that compound 12 showed speciﬁcity
for the malignant cells (Figure 7). H&E staining of the PDAC
specimens revealed that uptake of 12 occurred in ductal tissue
epithelial cells, similar to the ex vivo staining pattern (Figures
6A and 7). This is consistent with the fact that pancreatic ductal
epithelial cells give rise to PDAC.20 Furthermore, the
accumulation of 12 in PDAC mouse acinar cells (Figure 7D)

■

METHODS
Prediction of Physicochemical Properties and Molecular Modeling. Physicochemical partition coeﬃcient (log D)
values at pH 7.4 were calculated using Marvin and JChem
calculator plugins (ChemAxon, Budapest, Hungary). Molecular

Figure 3. Structures and summary of calculated physicochemical properties of 2, 12, and 13. Color-mapped surfaces show the molecular electrostatic
potential (blue is positive, green is neutral, and red is negative).
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Figure 4. | Subcellular colocalization of compound 12 in Capan-1 cells. Images of subcellular organelles stained with commercial ﬂuorescent trackers
(top row) are labeled 4’-6-diamidino-2-phenylindole (DAPI) (blue), ER (green), or Mito (green); bottom row contains merged view of compound
12 with ﬂuorescent organelle trackers.

acid, 2-(4-amino-2-hydroxybenzoyl)benzoic acid, 2-(8-hydroxy1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carbonyl)benzoic acid, and 1,8-naphthalene derivatives, were synthesized
according to described or modiﬁed literature protocols. In
general, overall good yields were obtained for most of the
ﬂuorophores included in this series with the exception of the
condensation products between 2-(2,4- dihydroxybenzoyl)benzoic acid and 8-amino naphthol derivatives 7 and 8, where
the major isolated product corresponded to ﬂuorescein. All
compounds were isolated by ﬂash column chromatography or
preparative thin-layer chromatography and characterized by
NMR and high-resolution electrospray ionization mass
spectrometry.
UV−Vis Absorption and Fluorescence Spectroscopy.
UV−vis spectra were collected using a Cary 50 UV−vis
spectrophotometer at room temperature (rt) using a reducedvolume 1 cm quartz cuvette. Fluorescence spectra were

orbital, UV−vis spectra, and electrostatic map calculations were
performed using density functional theory modeling on gasphase B3LYP/6-31G optimized geometries using Gaussian
09.23
Synthesis of Fluorescent Probes. Seminaphthoﬂuorescein, seminaphthorhodaﬂuors, and seminaphthorhodamines
(Figure 1) were synthesized in two to three steps. The initial
step involved the condensation of hydroxybenzophenones with
the corresponding naphthols in a mixture of CH3SO3H/TFA
1:1 at 80 °C for 16−24 h to produce the lactones or
carboxylates. Subsequent Fisher esteriﬁcation to produce the
methyl ester derivatives was carried out in MeOH catalyzed by
either H2SO4 or HCl. Further alkylation was attained by
treatment of either the carboxylate or methyl ester intermediate
with methyl iodide in the presence of K2CO3 in dimethylformamide to produce the corresponding methyl ethers. The
required starting materials, 2-(2,4-dihydroxybenzoyl)benzoic
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Figure 5. In vivo organ biodistribution kinetics of synthesized compounds vs MB-normalized ﬂuorescence intensity. Mean organ ﬂuorescence
intensity following systemic administration of (A) compound 2, (B) compound 12, (C) compound 13, or (D) MB.

collected on a Cary Eclipse ﬂuorescence spectrophotometer
(Agilent Technologies). All absorption spectra were reference
corrected. Fluorescence spectra were corrected for the
wavelength-dependent response of the R928 photomultiplier
tube using a manufacturer-generated correction ﬁle. Quantum
yields were reported as the average of multiple measurements
using multiple references. EEMs were collected over various
spectral regions, using 5 or 10 nm step sizes for emission and
excitation. The band pass for excitation and emission was 5−10
nm.
Cell Culture. The human PDAC cell line Capan-1 was
obtained from Dr. Rosalie Sears’s laboratory at Oregon Health
and Science University (OHSU) and was maintained in RPMI
medium (Gibco) in a humid atmosphere at 37 °C with 5%
CO2. All media were supplemented with 10% (v/v) fetal bovine
serum (FBS) and 1% (v/v) penicillin/streptomycin. Cell
viability was determined by Cell Titer-Blue assay. Monolayers
of 104 Capan-1 cells were seeded in triplicate in 96-well plates
and incubated with decreasing concentration from 100 μM of
each compound in growth media containing 10% FBS. After 24
h incubation time, 20 μL of Cell Titer-Blue reagent was added
into each well and culture cells were incubated for additional 2
h. Fluorescence intensity in each well was recorded at 560/590
nm using a SpectraMax M5 Microplate Reader. The halfmaximal inhibitory concentrations (IC50) of 2, 12, and 13 were
determined by interpolating values in the graph (% cell viability
vs ﬂuorophore concentration). For the comparison of cellular
uptake rates in Capan-1 cells, the absorbance of the media was
measured as background, and the absorbance of the supernatant was obtained to determine the cellular uptake, using the
absorbance of 10 μM ﬂuorophore in cell-free media as the
standard reference.

In Vitro Live Cell Imaging. Monolayers of 104 Capan-1
cells were seeded in triplicate in eight-well plates and incubated
for 24 h in growth mediun containing 10% FBS and were
allowed to attach. For subcellular colocalization experiments,
the medium was extracted and cells were washed with
phosphate-buﬀered saline (PBS), and phenol red-free growth
medium was added to each well. Organelle trackers were added
to each well, and incubated with the ﬂuorophore of interest
(ﬁnal concentration 0.5 μM) for 1 h. Cells were washed with
PBS and ﬁxed with 2% paraformaldehyde (PFA). Fluorescence
microscopy was carried out using a Zeiss inverted microscope
with an Axioscan ﬂuorescence camera for imaging. The ﬁnal
concentrations of organelle trackers used were as follows: DAPI
0.5 μM, Mito-tracker green 0.5 μM, and ER-tracker green 1
μM.
Animals. Approval for the use of all animals in this study
was obtained from the Institutional Animal Care and Use
Committee (IACUC) at OHSU. Male CD-1 mice weighing
22−24 g were purchased from Charles River Laboratories
(Wilmington, MA). Genetically engineered mouse models of
PDAC based on the targeted expression of an oncogenic KRAS
mutation (KRASG12D) in the mouse pancreas were used to
model the human disease. Mice expressing the KRAS mutation
alone, termed “KC mice”, develop the full range of intraductal
neoplastic lesions (PanINs) that are histologically indistinguishable from human PanINs. The mice develop PanINs with 100%
penetrance, but these lesions do not progress to metastatic
disease.19,24 A modiﬁcation of the KC mouse that was
developed in the laboratory of Dr. Rosalie Sears (Department
of Molecular & Medical Genetics, Oregon Health and Science
University) was used to more closely model human PDAC.
This mouse model, termed “KMC mice”, included overexpression of the wild-type Myc oncogene,25,26 similar to their
159
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Figure 6. Ex vivo microscopy images of control and PDAC tissue slides stained with compound 12 and real-time intraoperative ﬂuorescence imaging
of PDAC tumor-bearing mice injected with compound 12. (A) Microscopy images of compound 12 stained pancreas tissue. (B) The location of the
pancreas in the peritoneal cavity is shown outlined in yellow, with (top) and without (bottom) compound 12 administration. (C) Macroscopic
images of resected pancreas tissue from PDAC tumor-bearing mice ex vivo either following systemic administration of compound 12 (top) or from
an uninjected PDAC tumor-bearing mouse (bottom) conﬁrming the lack of pancreas ﬂuorescence without 12.

focused onto the surgical ﬁeld through a liquid light guide and
used unﬁltered for white light illumination. For ﬂuorescence
detection, the light source was ﬁltered using a 545 ± 12.5, 620
± 30, or 650 ± 22.5 nm bandpass excitation ﬁlter for
compounds 2 and 12, compound 13, and MB ﬂuorescence
excitation, respectively. The resultant ﬂuorescence was
collected using a 605 ± 35, 700 ± 37.5, or 720 ± 30 nm
bandpass emission ﬁlter for compounds 2 and 12, compound
13, and MB image collection, respectively. All ﬁlters were
obtained from Chroma technology (Bellows Falls, VT).
Camera exposure times ranged from 50 to 200 ms for
ﬂuorescence image collection. All images collected for
comparison between treatment groups were acquired with the
same exposure time and are displayed under equal normalized
brightness and contrast levels where indicated.
Systemic Administration of Fluorescent Compounds.
For initial in vivo testing and biodistribution studies, 100 nmol
of compounds 2, 12, and 13 were injected systemically.
Fluorophores were diluted in PBS. For comparison with
previous studies, 120 nmol MB was injected systemically. Mice
were administered blank PBS for control images (n = 3 mice

previously published breast cancer mouse models.27 This PC
mouse model developed PanIN lesions by 10 weeks of age and
rapidly progressed to PDAC, including metastatic disease, more
closely representing the human disease (Sears Lab OHSU,
unpublished data). Both KC and KMC mice were used to
assess compound 12 accumulation in PDAC. All animals were
placed on 5V75 chlorophyll-free diet from TestDiet (St. Louis,
MO) 1 week before any imaging studies. Before surgery, mice
were anaesthetized with 100 mg/kg ketamine and 10 mg/kg
xylazine (Patterson Veterinary, Devens, MA). The peritoneal
cavity was surgically exposed by removal of the overlying skin
and muscle tissue to image ﬂuorophore biodistribution
following intravenous injection.
Intraoperative Fluorescence Imaging System. In vivo
murine biodistribution images and macroscopic images of
resected tissues were acquired using a custom-built small animal
imaging system capable of real-time color and ﬂuorescence
imaging. The imaging system consists of a QImaging EXi Blue
monochrome camera (Surrey, British Columbia, CA) for
ﬂuorescence detection with a removable Bayer ﬁlter for
collecting co-registered color and ﬂuorescence images. A
PhotoFluor II light source (89 North, Burlington, VT) was
160
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Figure 7. Ex vivo pathology of resected PDAC tissue. Microscopy images of H&E, pan-cytokeratin, and compound 12 stained slides showing
representative (A) small, (B) medium, and (C) large-duct-type adenocarcinoma tissue as well as (D) acinar cells resected from PDAC-bearing mice
injected with 12. Pan-cytokeratin antibody staining highlights PDAC cells. Comparison of the ﬂuorescence images obtained with 12 to those
obtained with the antibody conﬁrms their similar PDAC-staining patterns.
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previously stained for cytokeratin expression were unmounted
and rinsed with PBS to remove residual mournting media
before H&E staining. Images were acquired on an Axio
Observer inverted ﬂuorescence microscope (Zeiss, Thornwood,
NY) at 10, 20, or 40× magniﬁcation. A PhotoFluor II was used
unﬁltered for H&E color images and ﬁltered using a 545 ± 12.5
or 470 ± 20 nm bandpass excitation ﬁlter for compound 12 or
Atto 488 excitation, respectively. Color images were collected
using an Axiocam 105 camera (Zeiss) and ﬂuorescence images
were collected using an Axiocam 506 camera (Zeiss), where a
605 ± 35 or 525 ± 25 nm bandpass emission ﬁlter was used for
compound 12 or Atto 488 ﬂuorescence image collection,
respectively.

per group, 5 groups). For PDAC tumor mice model testing 100
nmol of compound 12 was injected systemically (n = 5 mice).
In Vivo Biodistribution Imaging. The biodistribution of
compounds 2, 12, and 13 was assessed using the intraoperative
ﬂuorescence imaging system to collect images of the peritoneal
cavity. The peritoneal cavity was exposed, and images were
collected so that the bladder, adipose tissue, intestine, kidney,
liver, muscle, pancreas, spleen, and stomach were visible within
the ﬁeld of view. For initial biodistribution studies, images were
collected immediately after injection and at 5, 15, 30, 60, 120,
and 240 min following injection. For MB injected mice, images
were collected for the same time course, but only up to 60 min
due to the rapid clearance of MB. For PDAC tumor-bearing
mice, images were collected immediately after injection and at
5, 15, 30, 60, and 90 min following injection. Vehicle-injected
control animals were imaged for the same time course as the
ﬂuorophore-injected animals for initial testing or immediately
following injection only for studies involving MB or PDAC
tumor-bearing mice to assess tissue autoﬂuorescence for
comparison to injected animals. Fluorophore biodistribution
kinetics were measured using region-of-interest analysis on
images collected of the peritoneal cavity. Mean ﬂuorescence
intensities in each organ or tissue type were measured from
images collected at each time point. All intensities were
normalized to the muscle intensity at that time point by
dividing by the measured muscle intensity. Using the
normalized ﬂuorescence intensities for each organ or tissue
type, mean intensities were calculated for each group. Upon
completion of initial biodistribution studies, animals were
euthanized and their organs were resected. Macroscopic images
of the resected organs were collected using the intraoperative
ﬂuorescence imaging system, and the mean ﬂuorescence
intensity of each resected organ was measured using regionof-interest analysis. Fluorescence intensities were normalized to
the muscle intensity in the same manner as in vivo
measurements. Mean intensities were calculated for each
group using the normalized values. For biodistribution studies
in PDAC tumor-bearing mice, only the pancreas was resected
and imaged following euthanasia.
Ex Vivo Fluorescence Microscopy, Pathology, and
Immunoﬂuorescence Staining. The resected pancreas
tissue from compound 12 in vivo biodistribution studies with
PDAC tumor-bearing mice was ﬁxed with 2% PFA for 12 h,
ﬂash frozen in optimal cutting temperature (OCT) compound
with liquid nitrogen, and stored at −80 °C. Cryosections were
cut at 10 m onto Superfrost Plus slides (Fisherbrand, Fisher
Scientiﬁc). Slides were mounted with Fluoromount-G (Southern Biotech, Birmingham, AL) and coverslipped. Serial sections
were obtained for cytokeratin immunoﬂuorescence microscopy,
enabling imaging of compound 12 and immunoﬂuorescence
labeling with 0.01 mg/mL of directly labeled anti-pancytokeratin conjugated to AlexaFluor 488 (eBioscience, San
Diego, CA). Brieﬂy, slides were rinsed with PBS for 2 min to
remove residual OCT. Then, slides were ﬁxed by immersion in
2% PFA for 15 min and washed with PBS for 5 min three times.
Primary antibody was incubated on the slides for 1 h at rt.
Following incubation, slides were washed with PBS three times
for 5 min each, then postﬁxed with PFA for 15 min, and washed
with PBS once for 5 min before mounting with FluoromountG. For cytokeratin immunoﬂuorescence controls, serial sections
were stained using the above immunoﬂuorescence procedure
but without antibody present in the staining solution that was
incubated on the slides. For H&E pathological analysis, slides

■

ASSOCIATED CONTENT

* Supporting Information
S

The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acsomega.6b00403.
Methods, characterization data, and optical properties of
new compounds, computer-assisted molecular calculations, macro- and microscopic imaging studies (PDF).

■

AUTHOR INFORMATION

Corresponding Author

*E-mail: strongin@pdx.edu.
ORCID

Lei Wang: 0000-0002-0664-2704
Robert M. Strongin: 0000-0003-3777-8492
Author Contributions

All authors contributed equally.
Notes

The authors declare no competing ﬁnancial interest.

■

ACKNOWLEDGMENTS
This work was supported by grants from the V Foundation for
Cancer Research, the Brenden-Colson Center for Pancreatic
Care, and the National Institutes of Health (via grant
R15EB016870). We thank Dr. Joe Gray for valuable discussion
and Dr. Rosalie Sears of OHSU for the genetically engineered
KMC mouse models and Capan-1 cells.

■

REFERENCES

(1) Siegel, R. L.; Miller, K. D.; Jemal, A. Cancer statistics, 2016. CaCancer J. Clin. 2016, 66, 7−30.
(2) Rahib, L.; Smith, B. D.; Aizenberg, R.; Rosenzweig, A. B.;
Fleshman, J. M.; Matrisian, L. M. Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and pancreas
cancers in the United States. Cancer Res. 2014, 74, 2913−2921.
(3) Stathis, A.; Moore, M. J. Advanced pancreatic carcinoma: current
treatment and future challenges. Nat. Rev. Clin. Oncol. 2010, 7, 163−
172.
(4) Li, D.; Xie, K.; Wolff, R.; Abbruzzese, J. L. Pancreatic cancer.
Lancet 2004, 363, 1049−1057.
(5) Michalski, C. W.; Weitz, J.; Buchler, M. W. Surgery Insight:
surgical management of pancreatic cancer. Nat. Clin. Pract. Oncol.
2007, 4, 526−535.
(6) Verbeke, C. S. Resection margins and R1 rates in pancreatic
cancer − are we there yet? Histopathology 2008, 52, 787−796.
(7) Provenzano, P. P.; Cuevas, C.; Chang, A. E.; Goel, V. K.; Von
Hoff, D. D.; Hingorani, S. R. Enzymatic targeting of the stroma ablates
physical barriers to treatment of pancreatic ductal adenocarcinoma.
Cancer Cell 2012, 21, 418−429.

162

DOI: 10.1021/acsomega.6b00403
ACS Omega 2017, 2, 154−163

ACS Omega

Article

(8) Choi, H. S.; Gibbs, S. L.; Lee, J. H.; Kim, S. H.; Ashitate, Y.; Liu,
F.; Hyun, H.; Park, G.; Xie, Y.; Bae, S.; Henary, M.; Frangioni, J. V.
Targeted zwitterionic near-infrared fluorophores for improved optical
imaging. Nat. Biotechnol. 2013, 31, 148−153.
(9) Sibrian-Vázquez, M.; Escobedo, J. O.; Lowry, M.; Fronczek, F. R.;
Strongin, R. M. Field effects induce bathochromic shifts in xanthene
dyes. J. Am. Chem. Soc. 2012, 134, 10502−10508.
(10) Sibrian-Vázquez, M.; Escobedo, J. O.; Lowry, M.; Strongin, R.
M. Progress toward red and near-infrared (NIR) emitting saccharide
sensors. Pure Appl. Chem. 2012, 84, 2443−2456.
(11) Yang, Y.; Lowry, M.; Schowalter, C. M.; Fakayode, S. O.;
Escobedo, J. O.; Xu, X.; Zhang, H.; Jensen, T. J.; Fronczek, F. R.;
Warner, I. M.; Strongin, R. M. An organic white light-emitting
fluorophore. J. Am. Chem. Soc. 2006, 128, 14081−14092.
(12) Yang, Y.; Lowry, M.; Xu, X.; Escobedo, J. O.; Sibrian-Vázquez,
M.; Wong, L.; Schowalter, C. M.; Jensen, T. J.; Fronczek, F. R.;
Warner, I. M.; Strongin, R. M. Seminaphthofluorones are a family of
water-soluble, low molecular weight, NIR-emitting fluorophores. Proc.
Natl. Acad. Sci. U.S.A. 2008, 105, 8829−8834.
(13) Owens, E. A.; Hyun, H.; Tawney, J. G.; Choi, H. S.; Henary, M.
Correlating molecular character of NIR imaging agents with tissuespecific uptake. J. Med. Chem. 2015, 58, 4348−4356.
(14) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.
Experimental and computational approaches to estimate solubility and
permeability in drug discovery and development settings. Adv. Drug
Delivery Rev. 2001, 46, 3−26.
(15) Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward,
K. W.; Kopple, K. D. Molecular properties that influence the oral
bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615−2623.
(16) Millard, M.; Gallagher, J. D.; Olenyuk, B. Z.; Neamati, N. A
selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers. J. Med. Chem. 2013, 56,
9170−9179.
(17) Wada, H.; Hyun, H.; Vargas, C.; Gravier, J.; Park, G.; Gioux, S.;
Frangioni, J. V.; Henary, M.; Choi, H. S. Pancreas-targeted NIR
fluorophores for dual-channel image-guided abdominal surgery.
Theranostics 2015, 5, 1−11.
(18) di Magliano, M. P.; Logsdon, C. D. Roles for KRAS in
pancreatic tumor development and progression. Gastroenterology 2013,
144, 1220−1229.
(19) Hingorani, S. R.; Petricoin Iii, E. F.; Maitra, A.; Rajapakse, V.;
King, C.; Jacobetz, M. A.; Ross, S.; Conrads, T. P.; Veenstra, T. D.;
Hitt, B. A.; Kawaguchi, Y.; Johann, D.; Liotta, L. A.; Crawford, H. C.;
Putt, M. E.; Jacks, T.; Wright, C. V. E.; Hruban, R. H.; Lowy, A. M.;
Tuveson, D. A. Preinvasive and invasive ductal pancreatic cancer and
its early detection in the mouse. Cancer Cell 2003, 4, 437−450.
(20) Bardeesy, N.; DePinho, R. A. Pancreatic cancer biology and
genetics. Nat. Rev. Cancer 2002, 2, 897−909.
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